Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 30th 2021

touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer.

Questions
1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51)
2. What are the current challenges to the widespread use of immunotherapy? (00:51-02:19)
3. What factors affect the decision to prescribe immunotherapy to a patient with NSCLC? (02:19-02:56)
4. What are the challenges to expanding who gets immunotherapy and how can these be overcome? (02:56-04:09)
5. What further research is needed? (04:09-05:09)

Disclosures: Lyudmila Bazhenova has been an advisory board member for Merck, Daichi Sankyo, Turning Point, Janssen, Novartis, Neuvogen, BMS and Boehringer Ingelheim. She also discloses stock for Epic Sciences.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2021 WCLC Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup